Although rare, extracerebral metastases of PXA have been reported, involving sites as diverse as the scalp, skull, orbit, chest wall, lung, and vertebrae.12,13 Vemurafenib, which inhibits BRAF V600E, has shown activity against gliomas with this mutation.14 However, since the combination of a MEK inhibitor, binimetinib, with a newer BRAF inhibitor, encorafenib, was shown to be more effective and better tolerated than vemurafenib in BRAF V600E-mutant melanoma,15 it was tried in the current case, with good response. This evidence concerns the gene MAP2K7 and pleomorphic xanthoastrocytoma.